Response to rituximab induction is a predictive biomarker in post-transplant lymphoproliferative disorder

The impact of microbiota on the immune response

ASH 2015: Highlights in mantle cell lymphoma

ASH 2015: Novel combination approaches for multiple myeloma

ASH 2015: Ibrutinib as first-line treatment for chronic lymphocytic leukaemia

First targeted therapy for multiple myeloma effective against hard-to-treat disease

Anti-Bcl2 therapy shows promise for relapsed/refractory multiple myeloma

Comment: Classification system based on cytogenetics and treatment response identifies leukaemia patients with high-risk clinical features

Comment: Study identifies genetic variant that signifies higher risk for avascular necrosis in children with acute leukaemia

Engineered cells to target multiple myeloma

Classification system based on cytogenetics and treatment response identifies leukaemia patients with high risk clinical features with outstanding outcomes

Study identifies genetic variant that signifies higher risk for avascular necrosis in children with acute leukaemia